Pahari Hirak, Tripathi Shikhar, Nundy Samiran
Department of Liver Transplant and Hepatobiliary Surgery, Sir Ganga Ram Hospital, New Delhi 110060, India.
Department of Surgical Gastroenterology and Liver Transplant, Sir Ganga Ram Hospital, New Delhi 110060, India.
World J Transplant. 2025 Sep 18;15(3):104500. doi: 10.5500/wjt.v15.i3.104500.
Frailty has emerged as a pivotal determinant of post-liver transplant (LT) outcomes, yet its integration into clinical practice remains inconsistent. Defined by functional impairments and reduced physiologic reserve, frailty transcends traditional metrics like the model for end-stage liver disease (MELD) score, demonstrating increasing predictive value for mortality beyond the immediate post-operative period. Recent findings suggest that frail recipients experience significantly higher mortality within the first 12 months following transplantation-a period when traditional monitoring often wanes. This raises critical questions about the adequacy of current assessment and follow-up protocols. The observed dissociation between MELD scores and long-term survival underscores the limitations of existing selection criteria. Frailty, as a dynamic and modifiable condition, represents an opportunity for targeted intervention. Prehabilitation programs focusing on nutritional optimization, physical rehabilitation, and psychosocial support could enhance resilience in transplant candidates, reducing their risk profile and improving post-transplant outcomes. Furthermore, these findings call for an expanded approach to post-transplant monitoring. Extending surveillance for frail recipients beyond standard timelines may facilitate early detection of complications, mitigating their impact on survival. Incorporating frailty into both pre- and post-transplant protocols could redefine how transplant centers evaluate and manage risk. This editorial advocates for a paradigm shift: Frailty must no longer be viewed as a secondary consideration but as a core element in LT care. By addressing frailty comprehensively, we can move toward more personalized, effective strategies that improve survival and quality of life for LT recipients.
衰弱已成为肝移植(LT)术后结局的关键决定因素,但其在临床实践中的整合仍不一致。衰弱由功能障碍和生理储备减少所定义,超越了诸如终末期肝病模型(MELD)评分等传统指标,显示出对术后即刻以外时期死亡率的预测价值不断增加。最近的研究结果表明,衰弱的受者在移植后的头12个月内死亡率显著更高,而这一时期传统监测往往减弱。这就引发了关于当前评估和随访方案是否充分的关键问题。观察到的MELD评分与长期生存之间的脱节凸显了现有选择标准的局限性。衰弱作为一种动态且可改变的状况,代表了进行有针对性干预的机会。专注于营养优化、身体康复和心理社会支持的预康复计划可以增强移植候选者的恢复力,降低他们的风险状况并改善移植后结局。此外,这些研究结果呼吁对移植后监测采取扩展方法。将衰弱受者的监测延长至标准时间线之外可能有助于早期发现并发症,减轻其对生存的影响。将衰弱纳入移植前和移植后方案中可以重新定义移植中心评估和管理风险的方式。这篇社论倡导一种范式转变:衰弱绝不能再被视为次要考虑因素,而应作为肝移植护理的核心要素。通过全面应对衰弱,我们可以朝着更个性化、有效的策略迈进,以提高肝移植受者的生存率和生活质量。